Our Global Statement on Patents & Intellectual Property

BeiGene’s Position

The protections provided by intellectual property (IP) are integral to BeiGene’s ability to research and develop new and innovative medicines. Biopharmaceutical research and development is a long, expensive, and high-risk venture, with an average development timeline of 10-15 years per medicine and a high potential for failure. Patents provide a critical incentive to the private sector to undertake the high cost and investment risk of pharmaceutical development. Therefore, companies would be unable to sustain the R&D process without IP protection. At BeiGene, we believe that responsible IP usage is the best way to drive both therapeutic innovation and access to treatment for all patients.

BeiGene recognizes that the cost of innovative medicines—particularly specialized treatments such as those for cancer—is a key concern for patients, healthcare providers, and governments. At BeiGene, both affordability and accessibility are central to our vision to provide life-changing medicines to many more patients around the world. This is a core value of our “patients first” approach—to medicine development, pricing, health system contracting, and patient support programs.

As a founding member of the Union for International Cancer Control’s Access to Oncology Medicines (ATOM) Coalition, BeiGene believes in increasing cancer care access in low and lower middle-income countries. The ATOM Coalition works alongside local governments and stakeholders in select countries to assess and address their oncology needs, including facilitating voluntary licensing and partnering with manufacturers to develop, register, and supply quality-assured cancer medicines at affordable prices. You can read more about BeiGene’s perspective on accessibility [here](#).